The Centre for Inflammation and Therapeutic Innovation (CiTI) at Queen Mary University of London represents a unique opportunity for a strategic partnership aimed at exploring, developing and testing innovative strategies for anti-inflammatory therapies.
It is a virtual centre designed to capitalise on the circularity of the medical knowledge developed at QMUL thus embracing a two-way bench-to-bedside approach.
CiTI stems from the world-class track record of the William Harvey Research Institute in inflammation research, bringing together many sections of the School of Medicine and Dentistry, and the whole College.
The drive behind CiTI is to position the science of inflammation as the common thread of several high penetrance and debilitating pathologies to aid translational impact via therapeutic innovation.
We hold the ambition to cohere the excellence of QMUL's strengths in biomedical sciences to achieve translational goals in the context of inflammatory disorders and their co-morbidities. The uncovering of new therapeutic targets merged with state-of-the-art interventions, diagnostics, prevention strategies and stratified medicine will therefore inform both defined or to be defined conditions of the patient population we serve. Thus, CiTI is a multi-dimensional collaborative venture to accelerate the application of research discoveries for improved patient care.